Could a common painkiller reduce breast cancer risk?

NCT ID NCT04542135

Completed Prevention Sponsor: Alison Stopeck Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This trial investigates whether sulindac, an NSAID, can reduce breast density in postmenopausal women at elevated risk for breast cancer. High breast density is a known risk factor for the disease. Participants take sulindac or a placebo daily for 12 months, and changes in breast density are measured by MRI.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sulindac, a nonsteroidal anti-inflammatory drug (NSAID)
What this could lead to: If it works, this could point toward a way to lower breast cancer risk by reducing breast density.
What could go wrong: This is a small, early-phase trial, so results may not be conclusive. Sulindac can cause gastrointestinal side effects and other NSAID-related risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm breast cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Show contact details

Locations

Cedars Sinai - Cancer

Los Angeles, California, 90048, United States
Stony Brook University Cancer Center

Stony Brook, New York, 11794, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.